PhaseRx, Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2017. For the quarter, the company reported loss from operations of $3.915 million compared with $2.114 million a year ago. Net loss was $4.125 million or $0.35 per basic and diluted share compared with $2.234 million or $4.19 per basic and diluted share a year ago.